세계의 바이오시밀러 시장(-2035년) : 약물 종류(mAbs, GCSF, 인슐린, 항응고제, rhGH, 테리파라타이드, GLP-1), 적응증, 경쟁 구도, 지역별

The global biosimilars market is projected to reach USD 72.29 billion by 2035 from USD 35.04 billion in 2025, at a CAGR of 7.5% during the forecast period. The expansion of the biosimilars market has been predominantly fueled by heightened awareness and education regarding the safety, efficacy, and interchangeability of biosimilar products. Additionally, favorable insurance coverage and reimbursement structures implemented by both public and private payers have played a crucial role in this growth, alongside an increasing demand for cost-effective biologic therapies. Nonetheless, the market faces challenges from escalating complexities in the manufacturing processes and intensifying competition, leading to significant pricing pressures that may hinder further growth.

The monoclonal antibodies segment is expected to grow at the highest CAGR during the study period.

Monoclonal antibodies (mAbs) such as infliximab, rituximab, adalimumab, trastuzumab, pembrolizumab, dupilumab, Ustekinumab, Risankizumab, and others are primarily utilized for the treatment of autoimmune disorders, various cancers, chronic illnesses, and select infectious diseases. The anticipated rise in patient demographics, coupled with increasing adoption rates and the impending patent expirations of several key biologics, is projected to drive demand in the mAb sector. These therapeutics are extensively employed in managing chronic and life-threatening conditions, notably cancer, rheumatoid arthritis, psoriasis, and inflammatory bowel disease, which are experiencing heightened global prevalence due to an aging populace and lifestyle-related risk factors. The emergence of biosimilars for these mAbs offers an opportunity to mitigate healthcare expenditures and improve access to essential therapies. With over 10-15 leading mAbs facing patent expirations within the next decade, competition is poised to intensify, piquing the interest of pharmaceutical companies in the mAb market. The affordability and extensive applicability of mAb biosimilars, particularly in oncology and autoimmune therapies, are likely to significantly contribute to future market growth.

The US is expected to grow at the highest CAGR in the global biosimilars market from 2025 to 2035.

The United States is projected to experience the highest compound annual growth rate (CAGR) in the global biosimilars market between 2025 and 2035. This rapid growth is largely driven by the expiration of patents on several blockbuster biologics and the increasingly favorable regulatory environment established by the Biologics Price Competition and Innovation Act (BPCIA). Over the next decade, the US is expected to see biosimilar entries for major biologics such as Keytruda (pembrolizumab), Stelara (ustekinumab), and Eylea (aflibercept), which are all multi-billion-dollar products. These launches will significantly expand the addressable market for biosimilars, particularly in oncology, immunology, and ophthalmology. Additionally, the growing payer and provider acceptance of biosimilars in the US healthcare system is accelerating uptake. For instance, biosimilars of adalimumab (Humira), the highest-selling biologic in the US for over a decade, began launching in 2023 with multiple entrants such as Amgen, Boehringer Ingelheim, and Sandoz. Early signs show that competitive pricing is starting to drive formulary access and payer adoption. Moreover, legislative and policy efforts, including Medicare reforms and price transparency regulations, are expected to further incentivize biosimilar use, leading to cost savings and greater market penetration. As more biosimilars gain interchangeable status, market dynamics are likely to mirror those seen in generics, thus supporting sustained growth in the US biosimilars sector over the next decade.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side-70% and Demand Side-30%
• By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
• By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion, Inc. (South Korea), Biocon (India), Dr. Reddy's Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), STADA Arzneimittel AG (Germany), Boehringer Ingelheim International GmbH (Germany), Samsung Biologics Co., Ltd. (South Korea), Amneal Pharmaceuticals LLC (US), Coherus BioSciences, Inc. (US), Bio-Thera Solutions, Ltd. (China), Aprogen Inc. (South Korea), Shanghai Henlius Biopharmaceuticals, Inc. (China).

Research Coverage:

This research report categorizes the biosimilars market by biosimilars market, by drug class [monoclonal antibodies (rituximab, infliximab, adalimumab, trastuzumab, Pembrolizumab, Dupilumab, Ustekinumab, Risankizumab, and other monoclonal antibodies), granulocyte colony-stimulating factor, insulin, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, anticoagulants, Aflibercept, GLP-1 antagonist, and other products), By indication (oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, type II diabetes, obesity, and other indications) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimilars market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the biosimilars market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising global demand for affordable alternatives to expensive biologic therapies, increasing number of biosimilar launches and approvals, Impending and ongoing patent expiry of blockbuster biologics, entry of emerging players with cost-efficient manufacturing capabilities), restraints (manufacturing complexities and high cost of biosimilars, intense competition, and pricing pressure among market players), opportunities (launch of GLP-1 biosimilars, increasing strategic partnerships and collaborations among biosimilar manufacturers, and growing focus on advanced R&D operating models), and Challenges (increased market competition between biosimilar manufacturers and originator biologic companies).
• Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the biosimilars market.
• Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biosimilars market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objective of primary research
• 2.2 MARKET ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
      • 2.2.1.1.1 Revenue share analysis of Sandoz Group AG
    • 2.2.1.2 MnM repository analysis
    • 2.2.1.3 Primary interviews
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOSIMILARS MARKET OVERVIEW
• 4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS AND COUNTRY
• 4.3 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 BIOSIMILARS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2035 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising global demand for affordable alternatives to expensive biologic therapies
    • 5.2.1.2 Increasing number of biosimilar launches and approvals
    • 5.2.1.3 Impending and ongoing patent expiry of blockbuster biologics
    • 5.2.1.4 Entry of emerging players with cost-efficient manufacturing capabilities
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Manufacturing complexities and high cost of biosimilars
    • 5.2.2.2 Intense competition and pricing pressure among market players
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Launch of GLP-1 biosimilars
    • 5.2.3.2 Increasing strategic partnerships and collaborations among biosimilar manufacturers
    • 5.2.3.3 Growing focus on advanced R&D operating models
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Increased market competition between biosimilar manufacturers and originator biologic companies
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Advanced bioprocessing & manufacturing technologies
    • 5.3.1.2 Analytical & characterization techniques
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 AI & ML
    • 5.3.2.2 Lab automation & robotics
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Microbial fermentation
    • 5.3.3.2 3D bioprinting & high-density cell culture
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 PATENT ANALYSIS
  • 5.7.1 LIST OF KEY PATENTS
• 5.8 PIPELINE ANALYSIS
  • 5.8.1 BIOSIMILAR PRODUCTS IN CLINICAL PIPELINE
  • 5.8.2 LIST OF KEY BIOLOGICS TO GO OFF-PATENT
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9.2 REGULATORY FRAMEWORK
• 5.10 REIMBURSEMENT SCENARIO ANALYSIS
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.11.2 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 2022-2024
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF SUPPLIERS
  • 5.13.4 BARGAINING POWER OF BUYERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET
• 5.17 IMPACT OF 2025 US TARIFF ON BIOSIMILARS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 KEY TARIFF RATES
  • 5.17.3 PRICE IMPACT ANALYSIS
  • 5.17.4 IMPACT ON COUNTRY/REGION
    • 5.17.4.1 North America
      • 5.17.4.1.1 US
    • 5.17.4.2 Europe
    • 5.17.4.3 Asia Pacific
  • 5.17.5 IMPACT ON UPSTREAM MANUFACTURING INDUSTRIES

6 BIOSIMILARS MARKET, BY DRUG CLASS

• 6.1 INTRODUCTION
• 6.2 MONOCLONAL ANTIBODIES
  • 6.2.1 RITUXIMAB
    • 6.2.1.1 Rising incidences of autoimmune diseases and cancer to boost segment growth
  • 6.2.2 INFLIXIMAB
    • 6.2.2.1 Loss of patent exclusivity to fuel adoption for treating autoimmune diseases
  • 6.2.3 ADALIMUMAB
    • 6.2.3.1 Cost-effectiveness and improved patient access to support segment growth
  • 6.2.4 TRASTUZUMAB
    • 6.2.4.1 Rising incidence of breast cancer to spur market growth
  • 6.2.5 PEMBROLIZUMAB
    • 6.2.5.1 Expansion of immunotherapy in oncology to propel segment growth
  • 6.2.6 DUPILUMAB
    • 6.2.6.1 High cost of originator therapy and ongoing label expansions to increase demand for affordable biosimilars
  • 6.2.7 USTEKINUMAB
    • 6.2.7.1 High annual treatment costs of original drug to augment segment growth
  • 6.2.8 RISANKIZUMAB
    • 6.2.8.1 Increased biologic-naive patient growth and high demand for targeted immunotherapies to fuel adoption
  • 6.2.9 OTHER MONOCLONAL ANTIBODIES
• 6.3 GRANULOCYTE COLONY-STIMULATING FACTOR
  • 6.3.1 RISING GLOBAL CANCER BURDEN AND INCREASING INVESTMENTS BY PHARMA COMPANIES TO PROPEL MARKET GROWTH
• 6.4 INSULIN
  • 6.4.1 HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH
• 6.5 ERYTHROPOIETIN
  • 6.5.1 RISING INCIDENCE OF BLOOD DISEASES TO AUGMENT MARKET GROWTH
• 6.6 RECOMBINANT HUMAN GROWTH HORMONE
  • 6.6.1 RISING INCIDENCE OF CACHEXIA AND LIVER DISEASES TO FUEL MARKET GROWTH
• 6.7 ETANERCEPT
  • 6.7.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE APPROVAL AND COMMERCIALIZATION OF ETANERCEPT BIOSIMILARS
• 6.8 FOLLITROPIN
  • 6.8.1 POPULARITY OF FOLLITROPIN IN INFERTILITY TREATMENT TO SPUR MARKET GROWTH
• 6.9 TERIPARATIDE
  • 6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST MARKET DEMAND
• 6.10 INTERFERONS
  • 6.10.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
• 6.11 ANTICOAGULANTS
  • 6.11.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO FUEL MARKET GROWTH
• 6.12 AFLIBERCEPT
  • 6.12.1 HIGH COST OF ORIGINATOR DRUG AND INCREASED PREVALENCE OF AGE-RELATED EYE DISEASES TO DRIVE SEGMENT
• 6.13 GLP-1 ANTAGONIST
  • 6.13.1 HIGH PREVALENCE OF DIABETES AND OBESITY TO AID MARKET GROWTH
• 6.14 OTHER DRUG CLASSES

7 BIOSIMILARS MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 ONCOLOGY
  • 7.2.1 HIGH PREVALENCE OF CANCER TO DRIVE MARKET
• 7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
  • 7.3.1 RISING LIFE EXPECTANCY AND GROWING GERIATRIC POPULATION TO AUGMENT MARKET GROWTH
• 7.4 CHRONIC DISEASES
  • 7.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO FUEL UPTAKE OF BIOSIMILARS
• 7.5 BLOOD DISORDERS
  • 7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND
• 7.6 GROWTH HORMONE DEFICIENCY
  • 7.6.1 INCREASING CASES OF GROWTH HORMONE DEFICIENCY AMONG ADULTS TO INCREASE DEMAND FOR BIOSIMILARS
• 7.7 INFECTIOUS DISEASES
  • 7.7.1 HIGH POPULATION DENSITY AND INDUSTRIALIZATION OF FOOD PRODUCTION TO DRIVE PREVALENCE IN EMERGING ECONOMIES
• 7.8 TYPE II DIABETES
  • 7.8.1 COST-EFFECTIVENESS AND HIGH EFFICACY TO DRIVE BIOSIMILAR ADOPTION FOR DIABETES
• 7.9 OBESITY
  • 7.9.1 INCREASING SEDENTARY LIFESTYLE AMONG ADULTS TO PROPEL MARKET GROWTH
• 7.10 OTHER INDICATIONS

8 BIOSIMILARS MARKET, BY REGION

• 8.1 INTRODUCTION
• 8.2 EUROPE
  • 8.2.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 8.2.2 GERMANY
    • 8.2.2.1 Acceptance of biosimilars by physicians over originator products to propel market growth
  • 8.2.3 UK
    • 8.2.3.1 Rising prevalence of life-threatening diseases to fuel demand for low-priced biosimilars
  • 8.2.4 FRANCE
    • 8.2.4.1 Increased government R&D investments for biosimilar drugs to augment market growth
  • 8.2.5 ITALY
    • 8.2.5.1 Favorable government regulations and reimbursement policies to propel market growth
  • 8.2.6 SPAIN
    • 8.2.6.1 Favorable patient incentives and high healthcare R&D expenditure to promote biosimilar use
  • 8.2.7 REST OF EUROPE
• 8.3 ASIA PACIFIC
  • 8.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 8.3.2 JAPAN
    • 8.3.2.1 High demand for affordable biologics and recent patent expiries of blockbuster biologics to drive market
  • 8.3.3 CHINA
    • 8.3.3.1 Increasing investments in pharmaceutical R&D and innovation to augment market growth
  • 8.3.4 INDIA
    • 8.3.4.1 Need for government healthcare expenditure reduction to propel adoption of biosimilars
  • 8.3.5 SOUTH KOREA
    • 8.3.5.1 Favourable government incentives to promote biosimilar use in clinical practice
  • 8.3.6 AUSTRALIA
    • 8.3.6.1 Launch of biosimilar-switching programs in healthcare settings to aid market adoption
  • 8.3.7 REST OF ASIA PACIFIC
• 8.4 NORTH AMERICA
  • 8.4.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 8.4.2 US
    • 8.4.2.1 US to dominate North American biosimilars market during forecast period
  • 8.4.3 CANADA
    • 8.4.3.1 Favorable government initiatives to drive growth in biopharma research and manufacturing facilities
• 8.5 LATIN AMERICA
  • 8.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 8.5.2 BRAZIL
    • 8.5.2.1 Increased government pharmaceutical R&D investments for biosimilars to aid market growth
  • 8.5.3 MEXICO
    • 8.5.3.1 Well-developed regulatory landscape and high demand for chronic disease treatment to fuel biosimilar uptake
  • 8.5.4 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST
  • 8.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 8.6.2 GCC COUNTRIES
    • 8.6.2.1 Focus on local pharmaceutical R&D to augment market growth
  • 8.6.3 REST OF MIDDLE EAST
• 8.7 AFRICA
  • 8.7.1 INCREASED CANCER BURDEN AND NEED FOR AFFORDABLE ALTERNATIVES TO HIGH-COST BIOLOGICS TO BOOST ADOPTION
  • 8.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET, 2022-2024
• 9.3 REVENUE ANALYSIS, 2020-2024
• 9.4 MARKET SHARE ANALYSIS, 2024
• 9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 9.5.1 STARS
  • 9.5.2 EMERGING LEADERS
  • 9.5.3 PERVASIVE PLAYERS
  • 9.5.4 PARTICIPANTS
  • 9.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024
    • 9.5.5.1 Company footprint
    • 9.5.5.2 Region footprint
    • 9.5.5.3 Drug class footprint
    • 9.5.5.4 Indication footprint
• 9.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 9.6.1 PROGRESSIVE COMPANIES
  • 9.6.2 RESPONSIVE COMPANIES
  • 9.6.3 DYNAMIC COMPANIES
  • 9.6.4 STARTING BLOCKS
  • 9.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 9.6.5.1 Detailed list of key startups/SMEs
    • 9.6.5.2 Competitive benchmarking of key startups/SMEs
• 9.7 COMPANY VALUATION & FINANCIAL METRICS
  • 9.7.1 FINANCIAL METRICS
  • 9.7.2 COMPANY VALUATION
• 9.8 BRAND/PRODUCT COMPARISON
• 9.9 COMPETITIVE SCENARIO
  • 9.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 9.9.2 DEALS
  • 9.9.3 EXPANSIONS

10 COMPANY PROFILES

• 10.1 KEY PLAYERS
  • 10.1.1 SANDOZ GROUP AG
    • 10.1.1.1 Business overview
    • 10.1.1.2 Products offered
    • 10.1.1.3 Recent developments
      • 10.1.1.3.1 Product launches and approvals
      • 10.1.1.3.2 Deals
      • 10.1.1.3.3 Expansions
      • 10.1.1.3.4 Other developments
    • 10.1.1.4 MnM view
      • 10.1.1.4.1 Key strengths
      • 10.1.1.4.2 Strategic choices
      • 10.1.1.4.3 Weaknesses & competitive threats
  • 10.1.2 PFIZER INC.
    • 10.1.2.1 Business overview
    • 10.1.2.2 Products offered
    • 10.1.2.3 Recent developments
      • 10.1.2.3.1 Product approvals
      • 10.1.2.3.2 Deals
    • 10.1.2.4 MnM view
      • 10.1.2.4.1 Key strengths
      • 10.1.2.4.2 Strategic choices
      • 10.1.2.4.3 Weaknesses & competitive threats
  • 10.1.3 AMGEN INC.
    • 10.1.3.1 Business overview
    • 10.1.3.2 Products offered
    • 10.1.3.3 Products in pipeline
    • 10.1.3.4 Recent developments
      • 10.1.3.4.1 Product launches and approvals
      • 10.1.3.4.2 Deals
      • 10.1.3.4.3 Expansions
    • 10.1.3.5 MnM view
      • 10.1.3.5.1 Key strengths
      • 10.1.3.5.2 Strategic choices
      • 10.1.3.5.3 Weaknesses & competitive threats
  • 10.1.4 CELLTRION INC.
    • 10.1.4.1 Business overview
    • 10.1.4.2 Products offered
    • 10.1.4.3 Recent developments
      • 10.1.4.3.1 Product launches and approvals
      • 10.1.4.3.2 Deals
    • 10.1.4.4 MnM view
      • 10.1.4.4.1 Key strengths
      • 10.1.4.4.2 Strategic choices
      • 10.1.4.4.3 Weaknesses & competitive threats
  • 10.1.5 BIOCON
    • 10.1.5.1 Business overview
    • 10.1.5.2 Products offered
    • 10.1.5.3 Recent developments
      • 10.1.5.3.1 Product approvals
      • 10.1.5.3.2 Deals
      • 10.1.5.3.3 Other developments
    • 10.1.5.4 MnM view
      • 10.1.5.4.1 Key strengths
      • 10.1.5.4.2 Strategic choices
      • 10.1.5.4.3 Weaknesses & competitive threats
  • 10.1.6 DR. REDDY'S LABORATORIES LTD.
    • 10.1.6.1 Business overview
    • 10.1.6.2 Products offered
    • 10.1.6.3 Recent developments
      • 10.1.6.3.1 Product launches
      • 10.1.6.3.2 Deals
      • 10.1.6.3.3 Other developments
  • 10.1.7 ELI LILLY AND COMPANY
    • 10.1.7.1 Business overview
    • 10.1.7.2 Products offered
    • 10.1.7.3 Recent developments
      • 10.1.7.3.1 Product launches
      • 10.1.7.3.2 Deals
      • 10.1.7.3.3 Expansions
  • 10.1.8 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.1.8.1 Business overview
    • 10.1.8.2 Products offered
    • 10.1.8.3 Recent developments
      • 10.1.8.3.1 Product launches and approvals
      • 10.1.8.3.2 Deals
      • 10.1.8.3.3 Other developments
  • 10.1.9 FRESENIUS KABI AG
    • 10.1.9.1 Business overview
    • 10.1.9.2 Products offered
    • 10.1.9.3 Recent developments
      • 10.1.9.3.1 Product launches and approvals
      • 10.1.9.3.2 Deals
  • 10.1.10 STADA ARZNEIMITTEL AG
    • 10.1.10.1 Business overview
    • 10.1.10.2 Products offered
    • 10.1.10.3 Recent developments
      • 10.1.10.3.1 Product launches
      • 10.1.10.3.2 Deals
      • 10.1.10.3.3 Expansions
      • 10.1.10.3.4 Other developments
  • 10.1.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 10.1.11.1 Business overview
    • 10.1.11.2 Products offered
    • 10.1.11.3 Recent developments
      • 10.1.11.3.1 Product approvals
      • 10.1.11.3.2 Deals
      • 10.1.11.3.3 Expansions
  • 10.1.12 SAMSUNG BIOLOGICS
    • 10.1.12.1 Business overview
    • 10.1.12.2 Products offered
    • 10.1.12.3 Recent developments
      • 10.1.12.3.1 Product approvals
      • 10.1.12.3.2 Deals
      • 10.1.12.3.3 Expansions
  • 10.1.13 AMNEAL PHARMACEUTICALS LLC
    • 10.1.13.1 Business overview
    • 10.1.13.2 Products offered
    • 10.1.13.3 Recent developments
      • 10.1.13.3.1 Product approvals
      • 10.1.13.3.2 Deals
      • 10.1.13.3.3 Other developments
  • 10.1.14 COHERUS BIOSCIENCES
    • 10.1.14.1 Business overview
    • 10.1.14.2 Products offered
    • 10.1.14.3 Recent developments
      • 10.1.14.3.1 Deals
      • 10.1.14.3.2 Other developments
  • 10.1.15 BIO THERA SOLUTIONS
    • 10.1.15.1 Business overview
    • 10.1.15.2 Products offered
    • 10.1.15.3 Recent developments
      • 10.1.15.3.1 Product approvals
      • 10.1.15.3.2 Deals
  • 10.1.16 APROGEN
    • 10.1.16.1 Business overview
    • 10.1.16.2 Products offered
    • 10.1.16.3 Recent developments
      • 10.1.16.3.1 Product approvals
    • 10.1.16.4 Products in pipeline
  • 10.1.17 SHANGHAI HENLINUS BIOTECH, INC.
    • 10.1.17.1 Business overview
    • 10.1.17.2 Products offered
    • 10.1.17.3 Products in pipeline
    • 10.1.17.4 Recent developments
      • 10.1.17.4.1 Product approvals
      • 10.1.17.4.2 Deals
      • 10.1.17.4.3 Other developments
• 10.2 OTHER PLAYERS
  • 10.2.1 ALVOTECH
  • 10.2.2 AMEGA BIOTECH
  • 10.2.3 BIOCAD
  • 10.2.4 PROBIOMED S.A. DE C.V.
  • 10.2.5 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
  • 10.2.6 POLPHARMA BIOLOGICS GROUP
  • 10.2.7 NEUCLONE
  • 10.2.8 XENTRIA
  • 10.2.9 YL BIOLOGICS
  • 10.2.10 KASHIV BIOSCIENCES, LLC
  • 10.2.11 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • 10.2.12 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.
  • 10.2.13 CURATEQ BIOLOGICS PVT. LTD.

11 APPENDIX

• 11.1 DISCUSSION GUIDE
• 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 11.3 CUSTOMIZATION OPTIONS
• 11.4 RELATED REPORTS
• 11.5 AUTHOR DETAILS